公开(公告)号：US20250066487A1

公开(公告)日：2025-02-27

申请号：US18935875

申请日：2024-11-04

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung YONG ,  Ui-Jung JUNG ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Wonjun SON ,  Yangsoon LEE ,  Yeunju KIM ,  Eunsil SUNG ,  Youngkwang KIM ,  Youngdon PAK ,  Minji PARK ,  Jaehyun EOM ,  Hyoju CHOI ,  Moo Young SONG ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Eun-Jung LEE

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20220363763A1

公开(公告)日：2022-11-17

申请号：US17269784

申请日：2019-08-21

Applicant: ABL BIO INC.

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Uijung JUNG ,  YoungKwang KIM ,  Yeun Ju KIM ,  Youngdon PAK ,  Sang Hoon LEE ,  Weon-Kyoo YOU ,  Jaeho JUNG ,  Lei FANG ,  Wenqing JIANG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

公开(公告)号：US20220242961A1

公开(公告)日：2022-08-04

申请号：US17296752

申请日：2019-12-02

Applicant: ABL Bio Inc.

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Hyejin CHUNG ,  Uijung JUNG ,  Youngdon PAK ,  Jun Hyun JEONG ,  Yeunju KIM ,  Seawon AHN ,  Byungje SUNG

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided is an anti-4-1 BB antibody or an antigen-binding fragment thereof, and uses thereof.

公开(公告)号：US20240383983A1

公开(公告)日：2024-11-21

申请号：US18684660

申请日：2021-08-18

Applicant: ABL BIO, INC.

Inventor： Kyungjin PARK ,  Yangsoon LEE ,  Saeyi LIM ,  Kyeongsu PARK ,  Minkyu SEON ,  Wonjun SON ,  Hyejin CHUNG ,  Yeryoung YONG ,  Yong-Gyu SON ,  Yeunju KIM ,  Youngdon PAK

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an anti-B7-H4/anti-4-1BB bispecific antibody capable to effectively block the T-cell inhibitory effect of B7-H4 on the surface of tumor cells, and simultaneously activate 4-1BB on T-cells. The bispecific antibody may have high binding affinity to both of a B7-H4 protein (e.g., a human, monkey and mouse B7-H4 protein) and a 4-1BB protein (e.g., a human, monkey and mouse 4-1BB protein). The present disclosure also provides an anti-B7-H4 antibody specifically binds to B7-H4 protein.

公开(公告)号：US20220056136A1

公开(公告)日：2022-02-24

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA CO., LTD

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Hyejin CHUNG ,  Eunsil SUNG ,  Jiseon YOO ,  Minji PARK ,  Yong-Gyu SON ,  Hyoju CHOI ,  Eunjung KIM ,  Jaeho JUNG ,  Weon-Kyoo YOU ,  Sang Hoon LEE ,  Lei FANG ,  Wenqing JIANG

IPC: C07K16/28 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US20210284749A1

公开(公告)日：2021-09-16

申请号：US17053256

申请日：2019-06-26

Applicant: ABL BIO INC.

Inventor： Kyungjin PARK ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Yangsoon LEE ,  Mikyung CHANG ,  Jaehyoung JEON ,  Youngkwang KIM ,  Junhyun JEONG ,  Jiseon YOO ,  Yeunju KIM ,  Donghoon YEOM ,  Eunjung KIM ,  Bora LEE ,  Jinwon JUNG

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.